Valentini et al developed criteria for disease activity in a patient with systemic sclerosis. The authors are from multiple hospitals and universities in Europe.
Parameters:
(1) modified Rodnan skin score (17 sites scored 0 to 3, maximum 51)
(2) scleredema (increase in soft tissue mass due to dermal imbibition, with abolishment of skin contours and skin folds)
(3) change in skin (delta skin - Did your skin manifestations change during the last month?)
(4) digital necrosis (active digital ulcers ranging from small infarcts on the tips of fingers to gangrene of whole digits)
(5) change in vascular manifestations (delta vascular - Did your vascular manifestations change during the last month?)
(6) arthritis (symmetrical swelling and tenderness of the peripheral joints)
(7) carbon monoxide diffuse capacity (DLCO) by the single breath method
(8) change in heart and lung (delta heart/lung - Did your cardiopulmonary manifestations change during the last month?)
(9) Westergren erythrocyte sedimentation rate (ESR)
(10) serum complement (hypocomplementemia)
Parameter |
Finding |
Points |
---|---|---|
modified Rodnan skin score |
<= 14 |
0 |
|
> 14 |
1 |
scleredema |
absent |
0 |
|
present |
0.5 |
change in skin |
improved |
0 |
|
unchanged |
0 |
|
worsened |
2 |
digital necrosis |
absent |
0 |
|
present |
0.5 |
change in vascular manifestations |
improved |
0 |
|
unchanged |
0 |
|
worsened |
0.5 |
arthritis |
absent |
0 |
|
present |
0.5 |
carbon dioxide diffusing capacity |
>= 80% |
0 |
|
< 80% |
0.5 |
change in heart and lung |
improved |
0 |
|
unchanged |
0 |
|
worsened |
2 |
ESR by Westergren method |
<= 30 mm in first hour |
0 |
|
> 30 mm in first hour |
1.5 |
serum complement |
C3 and C4 levels normal |
0 |
|
C3 OR C4 levels decreased |
1 |
where:
• Earlier versions of the criteria used the Kahaleh total skin score, with a cutoff > 20.
total index =
= SUM(points for all 10 parameters)
Interpretation:
• minimum index: 0
• maximum index: 10
• An index >= 3 indicates active disease.
Purpose: To evaluate a patient with systemic sclerosis using the criteria of Valentini and the European Scleroderma Study Group.
Specialty: Immunology/Rheumatology
Objective: criteria for diagnosis, severity, prognosis, stage, disease progression
ICD-10: M34,